- A phase 2a study using Lomecel-B for Alzheimer's Disease is currently enrolling patients; a prior phase 1 study established excellent safety profile with some efficacy.
- The global Alzheimer's Disease market could reach $25 billion by 2027.
- Lomecel-B has several shots on goal; besides being advanced for Alzheimer's Disease, Longeveron is exploring its use for ARDS due to Covid-19, rare heart disease, and aging frailty.
- Longeveron had cash and cash equivalents of $25.7 million, short-term investments of $9.4 million and working capital of $32.7 million as of December 31, 2021; enough cash to fund operations into 2024.
For further details see:
Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market